Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

Loss of SMAD4 staining in pre-operative cell blocks is associated with distant metastases following pancreaticoduodenectomy with venous resection for pancreatic cancer.

Boone BA, Sabbaghian S, Zenati M, Marsh JW, Moser AJ, Zureikat AH, Singhi AD, Zeh HJ 3rd, Krasinskas AM.

J Surg Oncol. 2014 Aug;110(2):171-5. doi: 10.1002/jso.23606. Epub 2014 Mar 24.

PMID:
24665063
2.

Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.

Oshima M, Okano K, Muraki S, Haba R, Maeba T, Suzuki Y, Yachida S.

Ann Surg. 2013 Aug;258(2):336-46. doi: 10.1097/SLA.0b013e3182827a65.

PMID:
23470568
3.

Failure patterns in resected pancreas adenocarcinoma: lack of predicted benefit to SMAD4 expression.

Winter JM, Tang LH, Klimstra DS, Liu W, Linkov I, Brennan MF, DʼAngelica MI, DeMatteo RP, Fong Y, Jarnagin WR, Oʼreilly EM, Allen PJ.

Ann Surg. 2013 Aug;258(2):331-5. doi: 10.1097/SLA.0b013e31827fe9ce.

4.
5.

Pancreaticoduodenectomy with portal vein/superior mesenteric vein resection for patients with pancreatic cancer with venous invasion.

Wang WL, Ye S, Yan S, Shen Y, Zhang M, Wu J, Zheng SS.

Hepatobiliary Pancreat Dis Int. 2015 Aug;14(4):429-35.

6.

SMAD4 expression predicts local spread and treatment failure in resected pancreatic cancer.

Yamada S, Fujii T, Shimoyama Y, Kanda M, Nakayama G, Sugimoto H, Koike M, Nomoto S, Fujiwara M, Nakao A, Kodera Y.

Pancreas. 2015 May;44(4):660-4. doi: 10.1097/MPA.0000000000000315.

PMID:
25760429
7.

Rationale for en bloc vein resection in the treatment of pancreatic adenocarcinoma adherent to the superior mesenteric-portal vein confluence. Pancreatic Tumor Study Group.

Fuhrman GM, Leach SD, Staley CA, Cusack JC, Charnsangavej C, Cleary KR, El-Naggar AK, Fenoglio CJ, Lee JE, Evans DB.

Ann Surg. 1996 Feb;223(2):154-62.

8.

Loss of E-cadherin expression and outcome among patients with resectable pancreatic adenocarcinomas.

Hong SM, Li A, Olino K, Wolfgang CL, Herman JM, Schulick RD, Iacobuzio-Donahue C, Hruban RH, Goggins M.

Mod Pathol. 2011 Sep;24(9):1237-47. doi: 10.1038/modpathol.2011.74. Epub 2011 May 6.

9.

Factors influencing outcome in patients undergoing portal vein resection for adenocarcinoma of the pancreas.

Banz VM, Croagh D, Coldham C, Tanière P, Buckels J, Isaac J, Mayer D, Muiesan P, Bramhall S, Mirza DF.

Eur J Surg Oncol. 2012 Jan;38(1):72-9. doi: 10.1016/j.ejso.2011.08.134. Epub 2011 Nov 3.

PMID:
22054617
10.

Long-term outcome of portomesenteric vein invasion and prognostic factors in pancreas head adenocarcinoma.

Jeong J, Choi DW, Choi SH, Heo JS, Jang KT.

ANZ J Surg. 2015 Apr;85(4):264-9. doi: 10.1111/ans.12502. Epub 2014 Feb 12.

PMID:
24641800
11.

A new preoperative prognostic scoring system to predict prognosis in patients with locally advanced pancreatic body cancer who undergo distal pancreatectomy with en bloc celiac axis resection: a retrospective cohort study.

Miura T, Hirano S, Nakamura T, Tanaka E, Shichinohe T, Tsuchikawa T, Kato K, Matsumoto J, Kondo S.

Surgery. 2014 Mar;155(3):457-67. doi: 10.1016/j.surg.2013.10.024. Epub 2013 Nov 2.

PMID:
24462074
12.

High-grade dysplasia and adenocarcinoma are frequent in side-branch intraductal papillary mucinous neoplasm measuring less than 3 cm on endoscopic ultrasound.

Wong J, Weber J, Centeno BA, Vignesh S, Harris CL, Klapman JB, Hodul P.

J Gastrointest Surg. 2013 Jan;17(1):78-84; discussion p.84-5. doi: 10.1007/s11605-012-2017-0. Epub 2012 Sep 5.

PMID:
22948841
13.

Adverse tumor biology associated with mesenterico-portal vein resection influences survival in patients with pancreatic ductal adenocarcinoma.

Wang F, Gill AJ, Neale M, Puttaswamy V, Gananadha S, Pavlakis N, Clarke S, Hugh TJ, Samra JS.

Ann Surg Oncol. 2014 Jun;21(6):1937-47. doi: 10.1245/s10434-014-3554-4. Epub 2014 Feb 21.

PMID:
24558067
14.
15.
16.

Is pancreatectomy with arterial reconstruction a safe and useful procedure for locally advanced pancreatic cancer?

Amano H, Miura F, Toyota N, Wada K, Katoh K, Hayano K, Kadowaki S, Shibuya M, Maeno S, Eguchi T, Takada T, Asano T.

J Hepatobiliary Pancreat Surg. 2009;16(6):850-7. doi: 10.1007/s00534-009-0190-7.

PMID:
19844653
17.

Pancreaticoduodenectomy with en bloc portal vein resection for pancreatic carcinoma with suspected portal vein involvement.

Poon RT, Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, Yeung C, Wong J.

World J Surg. 2004 Jun;28(6):602-8.

PMID:
15366753
18.

DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma.

Biankin AV, Morey AL, Lee CS, Kench JG, Biankin SA, Hook HC, Head DR, Hugh TB, Sutherland RL, Henshall SM.

J Clin Oncol. 2002 Dec 1;20(23):4531-42.

PMID:
12454109
19.

Portal vein resection in borderline resectable pancreatic cancer: a United Kingdom multicenter study.

Ravikumar R, Sabin C, Abu Hilal M, Bramhall S, White S, Wigmore S, Imber CJ, Fusai G; UK Vascular Resection in Pancreatic Cancer Study Group.

J Am Coll Surg. 2014 Mar;218(3):401-11. doi: 10.1016/j.jamcollsurg.2013.11.017. Epub 2013 Nov 27.

PMID:
24484730
20.

Use of a temporary intraoperative mesentericoportal shunt for pancreatic resection for locally advanced pancreatic cancer with portal vein occlusion and portal hypertension.

Bachellier P, Rosso E, Fuchshuber P, Addeo P, David P, Oussoultzoglou E, Lucescu I.

Surgery. 2014 Mar;155(3):449-56. doi: 10.1016/j.surg.2013.09.003. Epub 2014 Jan 21.

PMID:
24462078
Items per page

Supplemental Content

Write to the Help Desk